



ADULT MEDICATION GUIDELINE					
RIFAMPICIN					
Scope (Staff):	All WNHS Staff				
Scope (Area):	Obstetrics and Gynaecology				
This document should be read in conjunction with the Disclaimer.					

Quick Links

DoseAdministrationMonitoringPregnancy and Breastfeeding

Restrictions

IV - Formulary: Highly Restricted

Capsule, oral liquid - Formulary: Restricted

All use requires approval from a Clinical Microbiologist, Infectious Diseases Physician, Public Health Physician or Respiratory Physician.

Medication Class

Rifamycins

Presentation

Mixture: 100mg/5mL Capsule: 300mg

Vial: 600mg (10mL water for injections provided as diluent)

Storage

Store below 25°C, Protect from light.

Dose

Methicillin-resistant Staphylococcus aureus (MRSA) infection

As per Infectious diseases physician or clinical microbiologist as part of a multi-medication regimen

<u>Prophylaxis in contacts of patients with *Haemophilus influenzae* type b infection and <u>meningococcal disease</u></u>

As per Infectious diseases physician or clinical microbiologist

Administration

Refer to the Australian Injectable Drugs Handbook

Oral

Take at least half an hour before food

Monitoring

Obtain liver function tests, serum creatinine and complete blood count before treatment then monitor regularly during treatment

Stop if thrombocytopenia occurs

Pregnancy

1st Trimester: Considered safe to use2nd Trimester: Considered safe to use

3rd Trimester: Monitoring required (see below)

Rifampicin used in the last few weeks of pregnancy may be associated with an increased risk of haemorrhagic disorders in the newborn.

Maternal supplementation with vitamin K should be given during the last four to eight weeks of pregnancy and neonatal vitamin K at birth is recommended.

For more information, please contact KEMH Obstetric Medicines Information Service.

Breastfeeding

Considered safe to use

Breastmilk may be stained a red-orange colour

Comments

Urine, faeces, sweat and tears may become orange-red and soft contact lenses may be permanently stained

Rifampicin interacts with many drugs, so prescriber needs to be aware of all medicines being taken by patient

Be aware if patient has any loss of appetite, nausea, vomiting, unusual tiredness, jaundice, dark urine or pale faeces.

Rifampicin may can reduce effectiveness of contraceptive medications

Related Policies, Procedures & Guidelines

HDWA Mandatory Policies:

Meningococcal infection - meningitis, septicaemia Statutory notification alert

WNHS Clinical Practice Guidelines:

Antimicrobial Restriction Category List

Contraception

Meningococcal Disease

References

Australian Medicines Handbook. Rifampicin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Oct 6]. Available from: https://amhonline.amh.net.au/

Therapeutic Guidelines. Clearance antibiotics for invasive meningococcal or Hib disease. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2021 [cited 2021 Oct 6]. Available from: https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess

The Royal Women's Hospital. Rifampicin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Oct 6]. Available from: https://thewomenspbmg.org.au/

MIMS Australia. Rifadin in: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 Oct 6]. Available from: https://www.mimsonline.com.au

Society of Hospital Pharmacists of Australia. Rifampicin. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Oct 6]. Available from: http://aidh.hcn.com.au

Keywords	Rifampicin, MRSA, TB, tuberculosis, methicillin resistant staphylococcus aureus							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH Pharmacy Department							
Version Info:	4.0							
Date First Issued:	July 2015	Last Reviewed:	Oct 2021		Review Date:	Nov 2024		
Endorsed by:	Medicines and T	herapeutics Comm		Date:	02/11/2021			
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety				
	Std 3: Phealthcare Asso	reventing and Cont ciated Infection	Std 7: Blood Management					
	Std 4: Medication Safety				Std 8: Recognising and Responding to Acute Deterioration			
Printed or personally saved electronic copies of this document are considered uncontrolled.								
Access the current version from WNHS HealthPoint.								

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.